March 13, 2019

EMA Grants Orphan Medicinal Product Designation for Retrotope’s RT001 in the Treatment of Infantile Neuroaxonal Dystrophy (INAD), a PLA2G6 associated neurodegeneration (PLAN)

March 7, 2019

GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement

January 3, 2019

Immusoft Raises $20 Million In Series B Financing

December 13, 2018

Retrotope Announces First Dosing of RT001 in patients with Infantile Neuroaxonal Dystrophy (INAD)

October 17, 2018

Immusoft Receives Rare Pediatric Disease Designation For Treatment Of MPS I

October 3, 2018

VelosBio raises $58M in Series A round for antibody-drug conjugate development

September 12, 2018

Oncternal Announces First Patient Dosed in Phase 1b Clinical Trial of Cirmtuzumab in Combination with Paclitaxel in Patients with Breast Cancer

July 24, 2018

Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics

July 10, 2018

Jason Fontenot, Ph.D., Joins Immusoft As Chief Scientific Officer

July 9, 2018

Retrotope Announces Publication of Preclinical Research Showing Cognitive Improvements in a Huntington’s Disease Model Using Deuterated Polyunsaturated Fatty Acid (D-PUFA) Drug Candidate